FT
Schedule 13G filing
Franklin Templeton Inc disclosed a 7.7% stake in ACET
Franklin Templeton Inc reported owning 7.7% of Adicet Bio, Inc. (ACET) (724,138 shares) in a Schedule 13G filed Oct 28, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
From a public Schedule 13G, linked above. Not investment advice, and not a recommendation to buy or sell.